[Clinical-pathological characteristics and survival of triple negative breast cancer].
To investigate the clinical-pathological characteristics of triple negative breast cancer. The clinical-pathological characteristics of 690 breast cancer patients, all females, 127 being estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2 triple negative, were analyzed. The expression rate of P53, a tumor suppressor gene, of the triple negative breast cancer patients was 71.42% (75/127), significantly higher than that of the non-triple negative breast cancer patients (42.56%, P < 0.01), and the expression rate of epidermal growth factor receptor (EGFR) of the triple negative breast cancer was 59.74%, significantly higher than that of the non-triple negative breast cancer patients (22.06%, P = 0.013). The local lymph node metastasis rate of the triple negative breast cancer was 22.22%, significantly higher than that of the non-triple negative breast cancer patients (2.70%, P = 0.048). The 5-year overall survival (OS) rate and 10-year OS rate of he triple negative breast cancer patients were 79.67% and 63.15% respectively, both significantly lower than those of the non-triple negative breast cancer patients (88.59% and 83.28% respectively, both P = 0.001). The 5-year and 10-year disease free survival (DFS) rates of the triple negative breast cancer patients were 77.94% and 62.87% respectively, both significantly lower than those of the non-triple negative breast cancer patients (83.82% and 82.53% respectively, both P = 0.011), especially that within 36 months. Triple negative breast cancer is related with P53 and EGFR expression, and tends to metastasize to local lympho-nodes. The survival rate of triple negative breast cancer patients is significantly lower than that of non-triple negative breast cancer.